Development of Nodular Regenerative Hyperplasia (NRH) with Portal Hypertension Following the Administration of Oxaliplatin for the Recurrence of Colon Cancer

• Published in: Internal Medicine Vol. 54; no. 4; pp. 383 - 387
• Main Authors: Takaya, Hiroaki, Kawaratani, Hideto, Nakanishi, Keisuke, Takeyama, Shinya, Morioka, Chie, Sawai, Masayoshi, Toyohara, Masahisa, Fujimoto, Masao, Yoshiji, Hitoshi, Yamao, Junichi, Fukui, Hiroshi
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 01.01.2015
• Subjects: Antineoplastic Agents - adverse effects; Antineoplastic Agents - therapeutic use; colon cancer; Colonic Neoplasms - complications; Colonic Neoplasms - drug therapy; Esophageal and Gastric Varices - etiology; esophageal varices; Female; Humans; Hyperplasia - chemically induced; Hypertension, Portal - etiology; Liver - pathology; Middle Aged; Neoplasm Recurrence, Local - complications; Neoplasm Recurrence, Local - drug therapy; nodular regenerative hyperplasia (NRH); Organoplatinum Compounds - adverse effects; Organoplatinum Compounds - therapeutic use; oxaliplatin; Treatment Outcome
• ISSN: 0918-2918; 1349-7235
• DOI: 10.2169/internalmedicine.54.2461

Nodular regenerative hyperplasia (NRH) is associated with autoimmune and hematologic diseases and may lead to portal hypertension. We herein report a case of NRH diagnosed based on a liver biopsy. A 63-year-old woman developed esophageal varices and splenomegaly. She had undergone surgery for transverse colon cancer 24 years earlier and received systemic chemotherapy (FOLFOX4 including oxaliplatin) to treat lymph node metastasis 21 years after the operation. The present liver biopsy confirmed NRH, and, after two years, she received endoscopic injection sclerotherapy. Oxaliplatin was suspected to be the causative agent of NRH in this case. Therefore, physicians must consider the possibility of NRH in patients who receive chemotherapy.